GSA Capital Partners LLP Has $3.09 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Key Points

• GSA Capital Partners LLP significantly increased its stake in Pfizer by 513.6% during the first quarter, owning a total of 122,036 shares worth approximately $3.09 million.
• Pfizer's most recent earnings report showed earnings per share of $0.92, exceeding forecasts, although revenue declined by 7.8% year-over-year.
• The company declared a quarterly dividend of $0.43 per share, representing a 7.07% yield, with a payout ratio of 124.64%.

GSA Capital Partners LLP raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 513.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 122,036 shares of the biopharmaceutical company's stock after purchasing an additional 102,148 shares during the quarter. Pfizer accounts for about 0.3% of GSA Capital Partners LLP's investment portfolio, making the stock its 10th biggest position. GSA Capital Partners LLP's holdings in Pfizer were worth $3,092,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Bessemer Group Inc. grew its stake in Pfizer by 11.1% during the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after buying an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK grew its stake in Pfizer by 1.2% during the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock worth $35,817,000 after buying an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp bought a new stake in Pfizer during the first quarter worth about $8,283,000. Alta Advisers Ltd grew its stake in Pfizer by 69.6% during the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock worth $809,000 after buying an additional 13,100 shares during the last quarter. Finally, WCM Investment Management LLC lifted its position in shares of Pfizer by 8.7% during the first quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock worth $3,176,000 after purchasing an additional 10,051 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research reports. Bank of America upped their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. BMO Capital Markets reduced their target price on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. TD Cowen reduced their target price on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research report on Tuesday, April 22nd. Leerink Partners reduced their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research report on Wednesday, April 30th. Finally, Berenberg Bank reduced their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer has an average rating of "Moderate Buy" and a consensus target price of $28.28.

Pfizer Stock Up 0.8%

Shares of PFE stock traded up $0.20 during trading hours on Friday, hitting $23.49. 40,889,049 shares of the company were exchanged, compared to its average volume of 45,301,941. The business has a 50 day moving average of $24.36 and a two-hundred day moving average of $24.60. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.32. The company has a market capitalization of $133.52 billion, a PE ratio of 17.03, a PEG ratio of 0.86 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the prior year, the firm earned $0.82 earnings per share. The firm's revenue was down 7.8% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.3%. Pfizer's dividend payout ratio (DPR) is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.